Yan‐Fang Ye

726 total citations
30 papers, 431 citations indexed

About

Yan‐Fang Ye is a scholar working on Surgery, Oncology and Otorhinolaryngology. According to data from OpenAlex, Yan‐Fang Ye has authored 30 papers receiving a total of 431 indexed citations (citations by other indexed papers that have themselves been cited), including 16 papers in Surgery, 15 papers in Oncology and 13 papers in Otorhinolaryngology. Recurrent topics in Yan‐Fang Ye's work include Head and Neck Cancer Studies (13 papers), Intraperitoneal and Appendiceal Malignancies (4 papers) and Ovarian cancer diagnosis and treatment (4 papers). Yan‐Fang Ye is often cited by papers focused on Head and Neck Cancer Studies (13 papers), Intraperitoneal and Appendiceal Malignancies (4 papers) and Ovarian cancer diagnosis and treatment (4 papers). Yan‐Fang Ye collaborates with scholars based in China, United States and Hong Kong. Yan‐Fang Ye's co-authors include Wei‐Xiong Xia, Yan‐Qun Xiang, Xiang Guo, Hu L, Xing Lv, Ya‐Hui Yu, Liang‐Ru Ke, Ningyuan Zhu, Tingmei Yan and Jun Qiao and has published in prestigious journals such as Nature Communications, Journal of Clinical Oncology and PLoS ONE.

In The Last Decade

Yan‐Fang Ye

28 papers receiving 426 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Yan‐Fang Ye China	13	176	150	107	87	80	30	431
Jia Zhu China	13	131 0.7×	43 0.3×	58 0.5×	129 1.5×	65 0.8×	67	411
Mina Liu China	12	82 0.5×	13 0.1×	105 1.0×	50 0.6×	117 1.5×	24	304
Xiao-Xin Zhang China	16	155 0.9×	25 0.2×	97 0.9×	319 3.7×	94 1.2×	36	667
Xuan Wu China	12	54 0.3×	28 0.2×	23 0.2×	118 1.4×	59 0.7×	26	392
Qiuyuan Li China	13	58 0.3×	6 0.0×	57 0.5×	63 0.7×	127 1.6×	50	408
Fabio Beatrice Italy	14	124 0.7×	181 1.2×	230 2.1×	85 1.0×	72 0.9×	42	483
Daniel Vicario United States	7	297 1.7×	269 1.8×	207 1.9×	73 0.8×	243 3.0×	13	647
Yutaka Sugiyama Japan	12	90 0.5×	12 0.1×	74 0.7×	93 1.1×	106 1.3×	40	503
Weijian Zhong China	13	138 0.8×	19 0.1×	101 0.9×	148 1.7×	70 0.9×	29	526
U Harréus Germany	9	142 0.8×	45 0.3×	80 0.7×	118 1.4×	50 0.6×	20	371

Countries citing papers authored by Yan‐Fang Ye

Since Specialization

Citations

This map shows the geographic impact of Yan‐Fang Ye's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Yan‐Fang Ye with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Yan‐Fang Ye more than expected).

Fields of papers citing papers by Yan‐Fang Ye

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Yan‐Fang Ye. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Yan‐Fang Ye. The network helps show where Yan‐Fang Ye may publish in the future.

Co-authorship network of co-authors of Yan‐Fang Ye

This figure shows the co-authorship network connecting the top 25 collaborators of Yan‐Fang Ye. A scholar is included among the top collaborators of Yan‐Fang Ye based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Yan‐Fang Ye. Yan‐Fang Ye is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Wang, Lin, Nian Lu, Cheng Xu, et al.. (2025). Efficacy and safety of cadonilimab (PD-1/CTLA-4 bispecific) in combination with chemotherapy in anti-PD-1-resistant recurrent or metastatic nasopharyngeal carcinoma: a single-arm, open-label, phase 2 trial. BMC Medicine. 23(1). 152–152. 1 indexed citations

Liu, Qinqin, et al.. (2025). Efficacy and conversion outcome of chemotherapy combined with PD-1 inhibitor for patients with unresectable or recurrent gallbladder carcinoma: a real-world exploratory study. World Journal of Surgical Oncology. 23(1). 69–69.

Pang, Li, Lei‐Bo Xu, Zhijun Chen, et al.. (2025). Short-term prognosis of recipients with pretransplant exposure to immune checkpoint inhibitors after liver transplantation for hepatocellular carcinoma: A retrospective cohort study. Liver Research. 9(3). 221–230. 1 indexed citations

Liu, Guoying, Lin Wang, Jianwei Wang, et al.. (2024). Camrelizumab and apatinib plus induction chemotherapy and concurrent chemoradiotherapy in stage N3 nasopharyngeal carcinoma: a phase 2 clinical trial. Nature Communications. 15(1). 1029–1029. 9 indexed citations

Liu, Qinqin, Yan‐Fang Ye, Haoming Lin, et al.. (2023). Real-world experience of postoperative adjuvant chemoimmunotherapy in patients with perihilar cholangiocarcinoma at high risk of recurrence. Cancer Immunology Immunotherapy. 72(6). 1753–1761. 2 indexed citations

Wang, Dongyan, Yuting Lai, Hui Li, et al.. (2023). Determining the maximum tolerated dose of paclitaxel combined with fixed dose of cisplatin for hyperthermic intraperitoneal chemotherapy in ovarian cancer: A multicenter phase I trial. Gynecologic Oncology. 181. 125–132. 3 indexed citations

Li, Hui, et al.. (2023). A phase I dose-finding trial of hyperthermic intraperitoneal docetaxel combined with cisplatin in patients with advanced-stage ovarian cancer. Journal of Gynecologic Oncology. 35(1). e1–e1. 3 indexed citations

Lu, Nian, Wei‐Xiong Xia, Ying Huang, et al.. (2023). Efficacy and safety of sintilimab plus bevacizumab in metastatic nasopharyngeal carcinoma after failure of platinum-based chemotherapy: an open-label phase 2 study. EClinicalMedicine. 62. 102136–102136. 9 indexed citations

Liu, Guoying, Wang‐Zhong Li, De‐Shen Wang, et al.. (2022). Effect of Capecitabine Maintenance Therapy Plus Best Supportive Care vs Best Supportive Care Alone on Progression-Free Survival Among Patients With Newly Diagnosed Metastatic Nasopharyngeal Carcinoma Who Had Received Induction Chemotherapy. JAMA Oncology. 8(4). 553–553. 24 indexed citations

10.

Wang, Lin, Nian Lu, Jianwei Wang, et al.. (2022). Efficacy and safety of camrelizumab and apatinib combined with induction chemotherapy and concurrent chemoradiotherapy for stage T _any N3M0 nasopharyngeal carcinoma: A phase II QUINTUPLED trial.. Journal of Clinical Oncology. 40(16_suppl). 6012–6012. 1 indexed citations

11.

Wang, Lijuan, Yan‐Fang Ye, Huaiwu Lu, et al.. (2021). Efficacy of neoadjuvant hyperthermic intraperitoneal chemotherapy in advanced high-grade serous ovarian cancer (the NHIPEC trial): study protocol for a randomised controlled trial. BMJ Open. 11(12). e046415–e046415. 1 indexed citations

12.

Liu, Guoying, Wang‐Zhong Li, De‐Shen Wang, et al.. (2021). Capecitabine maintenance therapy after induction chemotherapy in newly diagnosed metastatic nasopharyngeal carcinoma: An open-label, randomized, controlled, phase trial.. Journal of Clinical Oncology. 39(15_suppl). 6044–6044. 3 indexed citations

13.

Xia, Wei‐Xiong, Hu L, Xing Lv, et al.. (2019). <p>Stage-specific concurrent chemoradiotherapy with or without induction chemotherapy for locoregionally advanced nasopharyngeal carcinoma: a retrospective, population-based study</p>. Cancer Management and Research. Volume 11. 9813–9827. 5 indexed citations

14.

Zhu, Ningyuan, Jun Qiao, Yan‐Fang Ye, & Tingmei Yan. (2018). Synthesis of mesoporous bismuth-impregnated aluminum oxide for arsenic removal: Adsorption mechanism study and application to a lab-scale column. Journal of Environmental Management. 211. 73–82. 51 indexed citations

15.

L, Hu, Wei‐Xiong Xia, Xing Lv, et al.. (2017). Concurrent chemoradiotherapy with 3-weekly versus weekly cisplatin in patients with locoregionally advanced nasopharyngeal carcinoma: A phase 3 multicentre randomised controlled trial (ChiCTR-TRC-12001979).. Journal of Clinical Oncology. 35(15_suppl). 6006–6006. 15 indexed citations

16.

Ke, Liang‐Ru, Wei‐Xiong Xia, Wen‐Ze Qiu, et al.. (2017). Safety and efficacy of lobaplatin combined with 5-fluorouracil as first-line induction chemotherapy followed by lobaplatin-radiotherapy in locally advanced nasopharyngeal carcinoma: preliminary results of a prospective phase II trial. BMC Cancer. 17(1). 134–134. 23 indexed citations

17.

Yu, Ya‐Hui, Wei‐Xiong Xia, Junli Shi, et al.. (2016). A model to predict the risk of lethal nasopharyngeal necrosis after re-irradiation with intensity-modulated radiotherapy in nasopharyngeal carcinoma patients. Chinese Journal of Cancer. 35(1). 59–59. 31 indexed citations

18.

Zhang, Haibo, Wei‐Xiong Xia, Xing Lü, et al.. (2013). A Novel Statistical Prognostic Score Model That Includes Serum CXCL5 Levels and Clinical Classification Predicts Risk of Disease Progression and Survival of Nasopharyngeal Carcinoma Patients. PLoS ONE. 8(2). e57830–e57830. 21 indexed citations

19.

Xia, Wei‐Xiong, Yan‐Fang Ye, Xing Lü, et al.. (2013). The Impact of Baseline Serum C-Reactive Protein and C-Reactive Protein Kinetics on the Prognosis of Metastatic Nasopharyngeal Carcinoma Patients Treated with Palliative Chemotherapy. PLoS ONE. 8(10). e76958–e76958. 23 indexed citations

20.

Feng, Mei, et al.. (2009). Estradiol upregulates the expression of oxytocin receptor in colon in rats. American Journal of Physiology-Endocrinology and Metabolism. 296(5). E1059–E1066. 34 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact